About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: IONS
- CUSIP: 46433010
- Previous Close: $44.59
- 50 Day Moving Average: $45.82
- 200 Day Moving Average: $39.44
- 52-Week Range: $121,202,000.00 - $19.59
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -61.93
- P/E Growth: -1.00
- Market Cap: $5.40B
- Outstanding Shares: 121,202,000
- Beta: 2.54
- Net Margins: -77.30%
- Return on Equity: -120.60%
- Return on Assets: -21.09%
Companies Related to Ionis Pharmaceuticals:
- Debt-to-Equity Ratio: 3.03%
- Current Ratio: 6.83%
- Quick Ratio: 6.75%
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?
12 brokerages have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $45.90 in the next twelve months.
When will Ionis Pharmaceuticals announce their earnings?
Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- BMO Capital Markets analysts commented, "We are incrementally more positive on IONS shares following Bayer's decision to advance FXI-Rx development. While Bayer will not assume development responsibilities until a Phase IIb dose selection study is completed, the collaboration was expanded to include next-gen LICA drug FXI-LRx, which increased the milestone payment to $75mn from $55mn. We believe the FXI program could be Ionis's most underappreciated asset, as investors assign little value and the opportunity remains upside to our and Street models, despite positive proof-of-concept data." (2/14/2017)
According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (2/13/2017)
Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)
Jefferies Group LLC analysts commented, "Pipeline update call focuses on volanesorsen, IONIS-GCGR-Rx & IONIS-FXI- Rx; and BIIB-partnered IONIS-DMPK-2.5-Rx discontinued due to inadequate potency in muscle in Ph1/2. Beyond highly anticipated Spinraza launch (our 2021E sales of $1.6B vs. BIIB cons of $1.4B, implying royalties to IONS of ~$250M), we view current pipeline products unlikely to drive further meaningful appreciation in IONS shares from its already hefty valuation (EV of ~$5.5B)." (1/6/2017)
Who owns Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Baillie Gifford & Co. (6.94%), State Street Corp (2.29%), Pinnacle Associates Ltd. (1.30%), Franklin Resources Inc. (0.89%) and Fiera Capital Corp (0.64%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke.
Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, William Harris Investors Inc., Fiera Capital Corp, Pinnacle Associates Ltd., Baillie Gifford & Co., Guggenheim Capital LLC, Raymond James Financial Services Advisors Inc. and Janus Capital Management LLC. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Patrick R O'neil, Sarah Boyce and Stanley T Crooke.
Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sicart Associates LLC, Deerfield Management Co., Renaissance Technologies LLC, Dimensional Fund Advisors LP, FMR LLC, Capstone Investment Advisors LLC, Franklin Resources Inc. and Russell Investments Group Ltd..
How do I buy Ionis Pharmaceuticals stock?
Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ionis Pharmaceuticals stock cost?
One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $44.59.